AT1 receptor blockade in experimental myocardial ischemia/reperfusion

Journal of the American Society of Nephrology

Volumn 10, Issue 1 SUPPL. 11, 1999, Pages

  Jalowy, Andreas ^a   Schulz, Rainer ^a   Heusch, Gerd ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; BRADYKININ; NITRIC OXIDE; PROSTAGLANDIN; ANGIOTENSIN RECEPTOR; BENZIMIDAZOLE DERIVATIVE; BIPHENYL DERIVATIVE; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TETRAZOLE DERIVATIVE;

ARRHYTHMOGENESIS; CORONARY ARTERY BLOOD FLOW; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPERFUSION INJURY; REVIEW; ANIMAL; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; HEART ARRHYTHMIA; PATHOLOGY; PHYSIOLOGY; STUNNED HEART MUSCLE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ARRHYTHMIA; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; MYOCARDIAL STUNNING; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES;

EID: 0032937685     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Linder C, Heusch G: ACE inhibitors for the treatment of myocardial ischemia? Cardiovasc Drugs Ther 4: 1375-1384, 1990
2. Lindpaintner K, Wilhelm MJ, Jin M, Unger T, Lang RE, Schölkens BA, Ganten D: Tissue renin-angiotensin systems: Focus on the heart. J Hypertens 5[Suppl 2]: S33-S38, 1987
3. Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ: Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res 69: 475-482, 1991
4. Ertl G, Kloner RA, Alexander RW, Braunwald E: Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation 65: 40-48, 1982
5. McAlpine HM, Cobbe SM: Neuroendocrine changes in acute myocardial infarction. Am J Med 84[Suppl 3A]: 61-66, 1988
6. Noda K, Sasaguri M, Ideishi M, Ikeda M, Arakawa K: Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs. Cardiovasc Res 27: 334-340, 1993
7. Balcells E, Meng QC, Johnson WH Jr, Oparil S, Dell'Italia LJ: Angiotensin II formation from ACE and chymase in human and animal hearts: Methods and species considerations. Am J Physiol 42: H1769-H1774, 1997
8. Baumgarten CR, Linz WL, Kunkel G, Schölkens BA, Wiemer G: Ramiprilat increases bradykinin outflow from isolated hearts of rat. Br J Pharmacol 108: 293-295, 1993
9. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JAM, Smith RD: Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45: 205-251, 1993
10. Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M: Regulation of gene transcription of angiotensin II receptor subtypes. J Clin Invest 95: 46-54, 1995
11. Spinale FG, de Gasparo M, Whitebread S, Hebbar L, Clair MJ, Melton M, Krombach S, Mukherjee R, Iannini JP: Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure. I. Effects on left ventricular performance and neurohormonal systems. Circulation 96: 2385-2396, 1997
12. Asano K, Dutcher DL, Port D, Minobe WA, Tremmel KD, Roden RL, Bohlmeyer TJ, Bush EW, Jenkin MJ, Abraham WT, Raynolds MV, Zisman LS, Perryman MB, Bristow MR: Selective downregulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium. Circulation 95: 1193-1200, 1997
13. 2 receptors in the normal and failing human heart. J Pharmacol Exp Ther 284: 323-336, 1998
14. Regitz-Zagrosek V, Friedel N, Heymann A, Bauer P, Neuβ M, Rolfs A, Steffen C, Hildebrandt A, Hetzer R, Fleck E: Regulation, chamber localization, and subtype distribution of angiotensin II receptors in human hearts. Circulation 91: 1461-1471, 1995
15. Regitz-Zagrosek V, Fielitz J, Dreysse R, Hildebrandt AG, Fleck E: Angiotensin receptor type I mRNA in human right ventricular endomyocardium biopsies: Downregulation in heart failure. Cardiovasc Res 35: 99-105, 1997
16. Haywood GA, Gullestad L, Katsuya T, Hutchinson HG, Pratt RE, Horiuchi M, Fowler MB: AT1 and AT2 angiotensin receptor gene expression in human heart failure. Circulation 95: 1201-1206, 1997
17. Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ: Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 268: 24539-24542, 1993
18. 2 receptors in the differential interaction between angiotensin II or III and alpha-2 adrenoceptors in the nucleus reticularis gigantocellularis in cardiovascular regulation and antinociception in rats. J Pharmacol Exp Ther 279: 795-802, 1996
19. Scheuer DA, Perrone MH: Angiotensin type 2 receptors mediate depressor phase of biphasic pressure response to angiotensin. Am J Physiol 33: R917-R923, 1993
20. Stoll M, Steckelings UM, Bottari SP, Metzger R, Unger T: The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 95: 651-657, 1995
21. Hübner R, Högemann AM, Sunzel M, Riddell JG: Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 11[Suppl 2]: S19-S25, 1997
22. Liu Y-H, Yang X-P, Sharov VG, Nass O, Sabbah HH, Peterson E, Carretero OA: Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: Role of kinins and angiotensin II type 2 receptors. J Clin Invest 99: 1926-1935, 1997
23. Wiemer G, Schölkens BA, Busse R, Wagner A, Heitsch H, Linz W: The functional role of angiotensin II-subtype AT2-receptors in endothelial cells and isolated ischemic rat hearts. Pharm Pharmacol Lett 3: 24-27, 1993
24. Seyedi N, Xu XB, Nasjletti A, Hintze TH: Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension 26: 164-170, 1995
25. Kuga T, Mohri M, Egashira K, Hirakawa Y, Tagawa T, Shimokawa H, Takeshita A: Bradykinin-induced vasodilation of human coronary arteries in vivo: Role of nitric oxide and angiotensin-converting enzyme. J Am Coll Cardiol 30: 108-112, 1997
26. Martorana PA, Kettenbach B, Breipohl G, Linz W, Schölkens BA: Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. Eur J Pharmacol 182: 395-396, 1990
27. Kitakaze M, Minamino T, Node K, Komamura K, Shinozaki Y, Mori H, Kosaka H, Inoue M, Hori M, Kamada T: Beneficial effects of inhibition of angiotensin-converting enzyme on ischemic myocardium during coronary hypoperfusion in dogs. Circulation 92: 950-961, 1995
28. Werrmann JG, Cohen SM: Comparison of effects of angiotensin-converting enzyme inhibition with those of angiotensin II receptor antagonism on functional and metabolic recovery in postisch-emic working rat heart as studied by [31P] nuclear magnetic resonance. J Cardiovasc Pharmacol 24: 573-586, 1994
29. Kohya T, Yokoshiki H, Tohse N, Kanno M, Nakaya H, Saito H, Kitabatake A: Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias: Beneficial effect of angiotensin II blockade. Circ Res 76: 892-899, 1995
30. Thomas GP, Ferrier GR, Howlett SE: Losartan exerts antiarrhythmic activity independent of angiotensin II receptor blockade in simulated ventricular ischemia and reperfusion. J Pharmacol Exp Ther 278: 1090-1097, 1996
31. Harada K, Komuro I, Hayashi D, Sugaya T, Murakami K, Yazaki Y: Angiotensin II type 1a receptor is involved in the occurrence of reperfusion arrhythmias. Circulation 97: 315-317, 1998
32. Muller CA, Opie LH, Peisach M, Pineda CA: Antiarrhythmic effects of the angiotensin converting enzyme inhibitor perindo-prilat in a pig model of acute regional myocardial ischemia. J Cardiovasc Pharmacol 19: 748-754, 1992
33. van Gilst WH, de Graeff PA, Wesseling H, de Langen CDJ: Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: A comparison of captopril, enalapril, and HOE 498. J Cardiovasc Pharmacol 8: 722-728, 1986
34. Webster MWI, Fitzpatrick MA, Nicholls MG, Ikram H, Wells JE: Effect of enalapril on ventricular arrhythmias in congestive heart failure. Am J Cardiol 56: 566-569, 1985
35. Werrmann JG, Cohen SM: Use of losartan to examine the role of the cardiac renin-angiotensin system in myocardial dysfunction during ischemia and reperfusion. J Cardiovasc Pharmacol 27: 177-182, 1996
36. Paz Y, Gurevitch J, Frolkis I, Matsa M, Kramer A, Locker C, Mohr R, Keren G: Effects of an angiotensin II antagonist on ischemic and nonischemic isolated rat hearts. Ann Thorac Surg 65: 474-479, 1998
37. 2 receptor antagonists on recovery of mechanical function after ischemia-reperfusion in isolated working rat hearts. Circulation 94: 3087-3089, 1996
38. Massoudy P, Becker BF, Gerlach E: Bradykinin accounts for improved postischemic function and decreased glutathione release of guinea pig heart treated with the angiotensin-converting enzyme inhibitor ramiprilat. J Cardiovasc Pharmacol 23: 632-639, 1994
39. Ehring T, Baumgart D, Krajcar M, Hümmelgen M, Kompa S, Heusch G: Attenuation of myocardial stunning by the ACE-inhibitor ramiprilat through a signal cascade of bradykinin and prostaglandins, but not nitric oxide. Circulation 90: 1368-1385, 1994
40. Hohlfeld T, Strobach H, Schrör K: Stimulation of prostacyclin synthesis by defibrotide: Improved contractile recovery from myocardial "stunning." J Cardiovasc Pharmacol 17: 108-115, 1991
41. Yoshiyama M, Kim S, Yamagishi H, Omura T, Tani T, Yanagi S, Toda I, Teragaki M, Akioka K, Takeuchi K, Takeda T: Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury. Am Heart J 128: 1-6, 1994
42. Liu Y-H, Yang X-P, Sharov VG, Sigmon DH, Sabbah HN, Carretero OA: Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension 27: 7-13, 1996
43. 1 receptor antagonist on chronic cardiac response to coronary artery ligation in rats. Cardiovasc Res 31: 568-576, 1996
44. Hartman JC, Hullinger TG, Wall TM, Shebuski RJ: Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition. Eur J Pharmacol 234: 229-236, 1993
45. Liu Y, Tsuchida A, Cohen MV, Downey JM: Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts. J Mol Cell Cardiol 27: 883-892, 1995
46. 1 angiotensin II receptors abolishes ischemic preconditioning in isolated rabbit hearts. J Mol Cell Cardiol 29: 129-139, 1997
47. Richard V, Ghaleh B, Bordeaux A, Giudicelli J-F: Comparison of the effects of EXP3174, an angiotensin II antagonist, and enalaprilat on myocardial infarct size in anaesthetized dogs. Br J Pharmacol 110: 969-974, 1993
48. Schwarz ER, Montino H, Fleischhauer J, Klues HG, vom Dahl J, Hanrath P: Angiotensin II receptor antagonist EXP 3174 reduces infarct size comparable with enalaprilat and augments preconditioning in the pig heart. Cardiovasc Drugs Ther 11: 687-695, 1997
49. 2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol 32: 1787-1796, 1998
50. Hartman JC, Wall TM, Hullinger TG, Shebuski RJ: Reduction of myocardial infarct size in rabbits by ramiprilat: Reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol 21: 996-1003, 1993
51. Hartman JC, Kurc GM, Hullinger TG, Wall TM, Sheehy RM, Shebuski RJ: Inhibition of nitric oxide synthase prevents myocardial protection by ramipril. J Pharmacol Exp Ther 3: 1071-1076, 1994
52. Liang C-S, Gavras H, Black J, Sherman LG, Hood WB Jr: Renin-angiotensin system inhibition in acute myocardial infarction in dogs: Effects on systemic hemodynamics, myocardial blood flow, segmental myocardial function, and infarct size. Circulation 66: 1249-1255, 1982
53. Daniell HB, Carson RR, Ballard KD, Thomas GR, Privitera PJ: Effects of captopril on limiting infarct size in conscious dogs. J Cardiovasc Pharmacol 6: 1043-1047, 1984
54. Hohlfeld T, Strobach H, Schrör K: Stimulation of endogenous prostacyclin protects the reperfused pig myocardium from ischemic injury. J Pharmacol Exp Ther 264: 397-405, 1993
55. de Carvalho Frimm C, Sun Y, Weber KT: Angiotensin II receptor blockade and myocardial fibrosis of the infarcted rat heart. J Lab Clin Med 129: 439-446, 1997
56. Yamagishi H, Kim S, Nishikimi T, Takeuchi K, Takeda T: Contribution of cardiac renin-angiotensin system to ventricular remodelling in myocardial-infarcted rats. J Mol Cell Cardiol 25: 1369-1380, 1993
57. Nishikimi T, Yamagishi H, Takeuchi K, Takeda T: An angiotensin II receptor antagonist attenuates left ventricular dilatation after myocardial infarction in hypertensive rats. Cardiovasc Res 29: 856-861, 1995
58. Schieffer B, Wirger A, Meybrunn M, Seitz S, Holtz J, Riede UN, Drexler H: Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 89: 2273-2282, 1994
59. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 327: 669-677, 1992
60. The Acute Infarction Ramipril Efficacy (AIRE) Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342: 821-828, 1993
61. ISIS-4 Collaborative Group: ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 345: 669-685, 1995
62. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania OC. Ney DE, Snavely DB, Chang PI: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of losartan in the elderly study, ELITE). Lancet 349: 747-752, 1997
63. Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T, DeKock M: Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 88: 1602-1609, 1993
64. Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L, Rucinska E: Losartan in heart failure: Hemodynamic effects and tolerability. Circulation 91: 691-697, 1995
65. Regitz-Zagrosek V, Neuss M, Fleck E: Effects of angiotensin receptor antagonists in heart failure: Clinical and experimental aspects. Eur Heart J 16[Suppl N]: 86-91, 1995
66. Azizi M, Chatellier G, Guyene T-T, Murieta-Geoffroy D, Ménard J: Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 92: 825-834, 1995